A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

Summary

The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.

Timeline

Start

2026-09-16

Primary completion

2029-05-17

Completion

2030-05-20

Drugs

Indications